Cargando…

Recombinant factor VIII Fc fusion protein for first-time immune tolerance induction: final results of the verITI-8 study

Inhibitor development remains a major challenge in factor VIII (FVIII) replacement therapy. verITI-8 is the first prospective study of a recombinant FVIII Fc fusion protein (rFVIIIFc; efmoroctocog alfa) for first-time immune tolerance induction (ITI) in males with severe hemophilia A and high-titer...

Descripción completa

Detalles Bibliográficos
Autores principales:	Malec, Lynn, Van Damme, An, Chan, Anthony K. C., Spasova, Mariya, Jain, Nisha, Sensinger, Charlotte, Dumont, Jennifer, Lethagen, Stefan, Carcao, Manuel, Peyvandi, Flora
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Hematology 2023
Materias:	Clinical Trials and Observations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10646781/ https://www.ncbi.nlm.nih.gov/pubmed/36735911 http://dx.doi.org/10.1182/blood.2022017780

Ejemplares similares

Post hoc longitudinal assessment of the efficacy and safety of recombinant factor IX Fc fusion protein in hemophilia B
por: Shapiro, Amy D., et al.
Publicado: (2023)

First study of extended half-life rFVIIIFc in previously untreated patients with hemophilia A: PUPs A-LONG final results
por: Königs, Christoph, et al.
Publicado: (2022)

Verity on Subject and Object
Publicado: (1871)

Design of a prospective observational study on the effectiveness and real-world usage of recombinant factor VIII Fc (rFVIIIFc) compared with conventional products in haemophilia A: the A-SURE study
por: Oldenburg, Johannes, et al.
Publicado: (2019)

Mr. Verity's Amalgamation Scheme
Publicado: (1920)

Residual burden of liver disease after HCV clearance in hemophilia: a word of caution in the era of gene therapy
por: La Mura, Vincenzo, et al.
Publicado: (2023)

Recombinant von Willebrand factor prophylaxis in patients with severe von Willebrand disease: phase 3 study results
por: Leebeek, Frank W. G., et al.
Publicado: (2022)

Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study
por: Usmani, Saad Z., et al.
Publicado: (2023)

Safety and efficacy of zanubrutinib in relapsed/refractory marginal zone lymphoma: final analysis of the MAGNOLIA study
por: Opat, Stephen, et al.
Publicado: (2023)

Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170
por: Zinzani, Pier Luigi, et al.
Publicado: (2023)

Role of radiotherapy to bulky sites of advanced Hodgkin lymphoma treated with ABVD: final results of FIL HD0801 trial
por: Ricardi, Umberto, et al.
Publicado: (2021)

Blinatumomab in pediatric relapsed/refractory B-cell acute lymphoblastic leukemia: RIALTO expanded access study final analysis
por: Locatelli, Franco, et al.
Publicado: (2022)

Managing surgery in hemophilia with recombinant factor VIII Fc and factor IX Fc: Data on safety and effectiveness from phase 3 pivotal studies
por: Chowdary, Pratima, et al.
Publicado: (2022)

Immune Tolerance Induction (ITI) with a pdFVIII/VWF Concentrate (octanate) in 100 Patients in the Observational ITI (ObsITI) Study
por: Escuriola Ettingshausen, Carmen, et al.
Publicado: (2022)

Morphological, Biochemical, and Climatological Analysis of Three Moroccan Henna Verities
por: El Massoudi, Soukaina, et al.
Publicado: (2019)

Recombinant Factor VIII Fc Inhibits B Cell Activation via Engagement of the FcγRIIB Receptor
por: Georgescu, Maria T., et al.
Publicado: (2020)

Glutathione for skin lightening: a regnant myth or evidence-based verity?
por: Sonthalia, Sidharth, et al.
Publicado: (2018)

COVID-19 Severity Is Associated with Differential Antibody Fc-Mediated Innate Immune Functions
por: Adeniji, Opeyemi S., et al.
Publicado: (2021)

iTi Conference in Turbulence 2018
por: Örlü, Ramis, et al.
Publicado: (2019)

6th iTi Conference
por: Peinke, Joachim, et al.
Publicado: (2016)

Fast and accurate mapping of long reads to complete genome assemblies with VerityMap
por: Bzikadze, Andrey V., et al.
Publicado: (2022)

Prophylaxis with a recombinant factor VIII Fc in hemophilia A: long-term follow-up on joint health, efficacy, and safety from phase 3 studies in children and adults
por: Konkle, Barbara A., et al.
Publicado: (2023)

Stanford Linear Accelerator Center selects Verity Ultraseek for public and internal Web Sites
Publicado: (2004)

7th iTi Conference in Turbulence
por: Örlü, Ramis, et al.
Publicado: (2017)

4th iTi Conference in Turbulence
por: Oberlack, Martin, et al.
Publicado: (2012)

Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3(mut+) AML ineligible for intensive chemotherapy
por: Wang, Eunice S., et al.
Publicado: (2022)

Recombinant factor VIII Fc for the treatment of haemophilia A
por: Hermans, Cedric, et al.
Publicado: (2021)

Real‐world data of immune tolerance induction using recombinant factor VIII Fc fusion protein in patients with severe haemophilia A with inhibitors at high risk for immune tolerance induction failure: A follow‐up retrospective analysis
por: Carcao, Manuel, et al.
Publicado: (2020)

What is in your cup of tea? DNA Verity Test to characterize black and green commercial teas
por: De Castro, Olga, et al.
Publicado: (2017)

Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia A: Final results from the ASPIRE extension study
por: Nolan, Beatrice, et al.
Publicado: (2020)

5th iTi Conference in Turbulence 2012
por: Talamelli, Alessandro, et al.
Publicado: (2014)

Distinct Metabolic Profile Associated with a Fatal Outcome in COVID-19 Patients during the Early Epidemic in Italy
por: Saccon, Elisa, et al.
Publicado: (2021)

Correction: What is in your cup of tea? DNA Verity Test to characterize black and green commercial teas
por: De Castro, Olga, et al.
Publicado: (2018)

Factor VIII-Fc Activates Natural Killer Cells via Fc-Mediated Interactions With CD16
por: Lagassé, H.A. Daniel, et al.
Publicado: (2021)

ITI Conference 2 : translators and interpreters mean business : proceedings of the second annual conference of the Institute of Translation and Interpreting, 29-30 April 1988, Hotel Russell, London
Publicado: (1988)

High mortality from Plasmodium falciparum malaria in children living with sickle cell anemia on the coast of Kenya
por: McAuley, Charlotte F., et al.
Publicado: (2010)

Reduced prevalence of SARS-CoV-2 infection in ABO blood group O
por: Barnkob, Mike Bogetofte, et al.
Publicado: (2020)

The association of ABO blood group with indices of disease severity and multiorgan dysfunction in COVID-19
por: Hoiland, Ryan L., et al.
Publicado: (2020)

Convalescent plasma to treat COVID-19
por: Bloch, Evan M.
Publicado: (2020)

Earlier the better: convalescent plasma
por: Tobian, Aaron A.R., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_jh060ihnni5r4v486lv445e7ct